Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation
Nova Oculus, formerly The Eye Machine, is pleased to share the results of a clinical study employing the Nova Oculus III microcurrent medical therapy device for the treatment of patients with the AMD disease through an article in the International Journal of Retina and Vitreous, published 18 June 2023.
The study, conducted by Kevin M. Parkinson, Eric C. Sayre, and Sheldon W. Tobe “demonstrated improved visual measures and is very encouraging as a potential treatment for dry AMD.” Based on this study and other supportive data, this treatment therapy that we developed was approved by Canada’s regulatory authority, Health Canada, for use in Canada last year in November.
Please see the full article here: https://journalretinavitreous.biomedcentral.com/counter/pdf/10.1186/s40942-023-00471-y.pdf
NOTE: We regret any potential confusion which may be caused by this article, which makes mention of our device, the Nova Oculus III, which was used in this clinical trial, as a MacuMira device. MacuMira was a contractor we used to arrange for the clinical study which is the subject of this article. In the article it mentions MacuMira as located in Palm Desert, California, while in reality Nova Oculus is headquartered here and MacuMira is located in Canada.
Source: BioMed Central Ltd
ABOUT NOVA OCULUS CANADA
NOVA OCULUS is the name of the pioneering new medical device engineered and developed to treat the dry form of Age-Related Macular Degeneration—and for the Canadian company of innovative people that created it. The Nova Oculus medical device has been certified as complying with the quality management standard set by the International Organization of Standardization (ISO) and the electrical safety standard set by the International Electrotechnical Commission (IEC). These certifications make future global regulatory approvals possible for the Nova Oculus medical device.